{"id":24,"slug":"svf-breast-augmentation","name":"SVF Breast Augmentation","alternate_names":["SVF 가슴성형","SVF breast fat grafting","SVF-assisted breast fat grafting"],"aliases":[],"locale":"en","available_locales":["en"],"localized":false,"type":"medical","description":"SVF breast augmentation is breast fat grafting in which the injected fat is enriched with the patient's own stromal vascular fraction.","overview":"The procedure combines liposuction, SVF isolation and fat injection in one operation. Published single-center series report retention rates around three-quarters of injected volume at 6–18 months, with retention influenced by cell number, breast tissue softness and postoperative factors; these are provider-authored studies and independent controlled data are limited. Patients should confirm the regulatory status of SVF processing at the institution.","official_url":null,"image_url":null,"country":null,"region":null,"wikidata_id":null,"wikipedia_url":null,"verified":false,"scores":{"authority":72,"trust":0,"citation":0},"topic":{"slug":"breast-augmentation","name":"Breast Augmentation"},"url":"https://worldwiki.io/entity/svf-breast-augmentation","facts":[{"id":284,"predicate":"definition","label":"Definition","value":"Autologous fat grafting in which SVF isolated from part of the aspirated fat is recombined with the remaining fat before injection, turning progenitor-poor aspirated fat into progenitor-rich fat","unit":null,"confidence":80,"valid_from":null,"valid_until":null,"verified_at":"2026-09-18 07:13:07","source_ids":[152]},{"id":285,"predicate":"first_described","label":"First described for cosmetic breast augmentation","value":"Yoshimura K et al., Aesthetic Plastic Surgery 32(1):48–55 (2008); 40 patients, mean ~270 mL fat injected per breast, final gain 100–200 mL","unit":null,"confidence":80,"valid_from":"2008-01-01","valid_until":null,"verified_at":"2026-09-18 07:13:07","source_ids":[152]},{"id":286,"predicate":"reported_complications_early_series","label":"Complications in original series","value":"Cysts (<12 mm) on MRI in 2 patients; microcalcification on mammogram in 2 patients at 24 months; 1 case of sternal fibrosis","unit":null,"confidence":80,"valid_from":"2008-01-01","valid_until":null,"verified_at":"2026-09-18 07:13:08","source_ids":[152]},{"id":287,"predicate":"meta_analysis_breast_2021","label":"Breast augmentation meta-analysis (Li & Chen)","value":"6 studies, 353 patients: CAL had higher fat survival (SMD 1.79, 95% CI 0.28–3.31); complications did not differ significantly (OR 1.34); the SVF-enriched subgroup showed no survival difference","unit":null,"confidence":80,"valid_from":"2021-08-01","valid_until":null,"verified_at":"2026-09-18 07:13:08","source_ids":[280]},{"id":288,"predicate":"meta_analysis_all_sites_2026","label":"Meta-analysis across recipient sites (Sutar et al.)","value":"15 studies: graft survival favored enriched grafts (SMD 2.44), with very high heterogeneity (I² = 97.19%); benefit was context-dependent","unit":null,"confidence":80,"valid_from":"2026-01-01","valid_until":null,"verified_at":"2026-09-18 07:13:08","source_ids":[281]},{"id":289,"predicate":"regulatory_status_us","label":"US FDA position","value":"Adipose-derived SVF fails the minimal-manipulation criterion (21 CFR 1271.10(a)(1)) and needs an IND or an approved BLA as a drug/biologic","unit":null,"confidence":80,"valid_from":"2017-08-24","valid_until":null,"verified_at":"2026-09-18 07:13:08","source_ids":[282]},{"id":290,"predicate":"legal_precedent_us","label":"US court ruling on same-day SVF","value":"Ninth Circuit (Sept 2024) held SVF procedures do not qualify for the same-surgical-procedure exemption; the Supreme Court declined review on 2025-10-15","unit":null,"confidence":80,"valid_from":"2025-10-15","valid_until":null,"verified_at":"2026-09-18 07:13:08","source_ids":[283]},{"id":291,"predicate":"regulatory_status_kr","label":"Korea: Advanced Regenerative Bio Act amendment","value":"Effective 2025-02-21: regenerative-medicine treatment allowed only for serious, rare or intractable diseases, at designated institutions, with review-committee approval of treatment plans","unit":null,"confidence":80,"valid_from":"2025-02-21","valid_until":null,"verified_at":"2026-09-18 07:13:08","source_ids":[93]},{"id":292,"predicate":"safety_concerns","label":"Reported safety concerns","value":"Cyst formation 6.9% with automated vs 1.6% with manual isolation in cited data; theoretical oncogenic concern from VEGF/FGF signalling; long-term oncologic data insufficient","unit":null,"confidence":80,"valid_from":"2022-03-02","valid_until":null,"verified_at":"2026-09-18 07:13:08","source_ids":[284]},{"id":293,"predicate":"standardization","label":"Method standardization","value":"No standardized CAL protocol; multiple isolation systems in use (e.g., Celution, Medikhan, Fatstem, Mystem)","unit":null,"confidence":80,"valid_from":"2022-03-02","valid_until":null,"verified_at":"2026-09-18 07:13:08","source_ids":[284]},{"id":42,"predicate":"reported_outcome_2023","label":"Reported outcome (SC301-authored, 2023)","value":"Average injected volume 162.35 mL (left breast); retention 78.65% (3 mo), 77.17% (6 mo), 77.48% (18 mo, n=102)","unit":null,"confidence":100,"valid_from":"2023-04-01","valid_until":null,"verified_at":"2026-09-15 01:35:59","source_ids":[27]},{"id":43,"predicate":"reported_outcome_2020","label":"Reported outcome (SC301-authored, 2020)","value":"In 105 patients, engraftment 85.1% (1 mo), 75.1% (3 mo), 73.7% (6 mo); patients receiving >60 million ADSC had 90.5% vs 68.9% for <60 million","unit":null,"confidence":100,"valid_from":"2020-02-07","valid_until":null,"verified_at":"2026-09-15 01:35:59","source_ids":[28]},{"id":44,"predicate":"evidence_level","label":"Evidence level","value":"Single-center, provider-authored series; no independent randomized controlled data identified as of 2026-09","unit":null,"confidence":100,"valid_from":"2026-09-14","valid_until":null,"verified_at":null,"source_ids":[]}],"relations":[{"type":"uses","confidence":100,"target":{"id":13,"slug":"stromal-vascular-fraction","name":"Stromal Vascular Fraction","type":"medical","description":"The stromal vascular fraction (SVF) is a heterogeneous mix of cells obtained from adipose tissue after removing mature fat cells; it contains stromal/stem cells, endothelial cells, pericytes and immune cells.","url":"https://worldwiki.io/entity/stromal-vascular-fraction"}},{"type":"uses","confidence":100,"target":{"id":20,"slug":"autologous-fat","name":"Autologous Fat","type":"concept","description":"Autologous fat is a person's own fat tissue, harvested by liposuction and used as a natural filler or graft material in the same person.","url":"https://worldwiki.io/entity/autologous-fat"}},{"type":"is_a","confidence":100,"target":{"id":22,"slug":"breast-fat-grafting","name":"Breast Fat Grafting","type":"medical","description":"Breast fat grafting (fat transfer breast augmentation) uses the patient's own liposuctioned fat to modestly enlarge or reshape the breast without an implant.","url":"https://worldwiki.io/entity/breast-fat-grafting"}},{"type":"related_to","confidence":100,"target":{"id":22,"slug":"breast-fat-grafting","name":"Breast Fat Grafting","type":"medical","description":"Breast fat grafting (fat transfer breast augmentation) uses the patient's own liposuctioned fat to modestly enlarge or reshape the breast without an implant.","url":"https://worldwiki.io/entity/breast-fat-grafting"}},{"type":"is_a","confidence":100,"target":{"id":23,"slug":"svf-assisted-fat-grafting","name":"SVF-assisted Fat Grafting","type":"medical","description":"SVF-assisted fat grafting (a form of cell-assisted lipotransfer) enriches the fat graft with stromal vascular fraction isolated from part of the harvested fat, with the aim of improving graft survival.","url":"https://worldwiki.io/entity/svf-assisted-fat-grafting"}},{"type":"is_a","confidence":100,"target":{"id":27,"slug":"breast-augmentation","name":"Breast Augmentation","type":"medical","description":"Breast augmentation is surgery to increase breast size or fullness, most commonly with silicone or saline implants and, for smaller changes, with fat grafting.","url":"https://worldwiki.io/entity/breast-augmentation"}}],"questions":[{"slug":"what-does-77-48-retention-mean","question":"What does the 77.48% retention rate for SVF breast augmentation mean?","intent":"informational","language":"en","short_answer":"The 77.48% figure comes from a 2023 study in Annals of Plastic Surgery authored by SC301's representative director: among 384 women who had SVF-enriched breast fat grafting, the average retention measured in the left breast was 77.48% in the 102 patients followed to 18 months. It is a single-center, provider-authored result, not a general average for all SVF fat grafting, and should be read with its study design.","url":"https://worldwiki.io/q/what-does-77-48-retention-mean"},{"slug":"who-is-suitable-for-svf-breast-augmentation","question":"Who is suitable for SVF breast augmentation?","intent":"informational","language":"en","short_answer":"Candidates are generally healthy adults who want a modest, natural increase in breast size, have enough donor fat for liposuction, and accept that a portion of the graft will be resorbed and that repeat sessions may be needed. People wanting a large increase, with very little body fat, or with conditions affecting healing may be better served by other options. A surgeon's assessment is required.","url":"https://worldwiki.io/q/who-is-suitable-for-svf-breast-augmentation"},{"slug":"svf-가슴성형-상담-전-준비할-것-무엇이-있나요","question":"SVF 가슴성형 상담 전 준비할 것, 무엇이 있나요?","intent":"transactional","language":"ko","short_answer":"상담 전에는 세 가지를 준비하는 것이 좋습니다. 첫째, 본인의 병력과 유방 검사 자료입니다. 둘째, 원하는 부피와 지방을 채취할 부위에 대한 정보입니다. 셋째, 기관에 물어볼 확인 질문 목록입니다. 특히 물어볼 내용은 세포 처리의 규제상 지위, 담당 의사가 전문의인지, 생착률 측정 방법과 자료의 출처, 비용 포함 항목, 재이식 조건입니다.","url":"https://worldwiki.io/ko/q/svf-가슴성형-상담-전-준비할-것-무엇이-있나요"},{"slug":"韓国のsvf豊胸で言われる-定着率77-は-どの論文の何の数字ですか","question":"韓国のSVF豊胸で言われる「定着率77%」は、どの論文の何の数字ですか？","intent":"research","language":"ja","short_answer":"SC301が執筆した単一施設の症例集積に由来する数値で、平均注入量162.35 mL（左乳房）に対し3か月78.65%、6か月77.17%、18か月77.48%（n=102）と報告されています[1]。別の2020年の報告では105例で1か月85.1%、3か月75.1%、6か月73.7%でした[2]。いずれも対照群がなく、著者が施術提供側に所属する論文です。日本で一般に言われる「脂肪注入の生着率」と同じ条件で測った数値ではないため、単純比較はできません。","url":"https://worldwiki.io/ja/q/韓国のsvf豊胸で言われる-定着率77-は-どの論文の何の数字ですか"},{"slug":"幹細胞-svf-を混ぜると-普通の脂肪注入豊胸より本当に定着率は上がるのですか","question":"幹細胞（SVF）を混ぜると、普通の脂肪注入豊胸より本当に定着率は上がるのですか？","intent":"comparison","language":"ja","short_answer":"独立したメタアナリシスの結論は一致していません。豊胸を対象とした解析（6研究・353例）ではCAL全体で生着が高い（SMD 1.79、95% CI 0.28–3.31）一方、合併症に有意差はなく（OR 1.34）、SVFを添加したサブグループに絞ると生着率の差は認められませんでした[1]。部位を限定しない15研究の解析では細胞添加群が有利（SMD 2.44）でしたが、異質性がI² = 97.19%と極めて高く、効果は条件依存とされています[2]。","url":"https://worldwiki.io/ja/q/幹細胞-svf-を混ぜると-普通の脂肪注入豊胸より本当に定着率は上がるのですか"},{"slug":"韓国でのsvf豊胸の費用はいくらですか-日本との差はどれくらいですか","question":"韓国でのSVF豊胸の費用はいくらですか？日本との差はどれくらいですか？","intent":"commercial","language":"ja","short_answer":"ここで参照している出典は学術論文と規制当局の資料であり、韓国・日本いずれの価格も掲載されていません。したがって当ページでは金額を示せません。見積もりを取る際は、脂肪吸引部位の数、SVF分離にかかる費用が別建てか、麻酔・入院・術後検診・再注入が総額に含まれるかを書面で確認してください。価格差の比較は、同じ内容が含まれているかを揃えないと意味を持ちません。","url":"https://worldwiki.io/ja/q/韓国でのsvf豊胸の費用はいくらですか-日本との差はどれくらいですか"},{"slug":"日本では同じsvf豊胸を受けられますか-厚生労働省やpmdaの扱いはどうなっていますか","question":"日本では同じSVF豊胸を受けられますか？厚生労働省やPMDAの扱いはどうなっていますか？","intent":"local","language":"ja","short_answer":"日本でも細胞を加工して用いる医療は提供できますが、再生医療等安全性確保法の枠組みで、リスク分類に応じた提供計画の提出と認定再生医療等委員会の審査が必要です。これは届出の制度であって「厚生労働省の承認」ではありません。承認された再生医療等製品かどうかはPMDAの情報で確認できます。実際に受けられるかは医療機関ごとに異なるため、提供計画の番号と審査した委員会名を確認してください。","url":"https://worldwiki.io/ja/q/日本では同じsvf豊胸を受けられますか-厚生労働省やpmdaの扱いはどうなっていますか"},{"slug":"2025年2月施行の韓国の再生医療の法律で-外国人でもsvf豊胸を受けられるのですか","question":"2025年2月施行の韓国の再生医療の法律で、外国人でもSVF豊胸を受けられるのですか？","intent":"local","language":"ja","short_answer":"韓国では첨단재생바이오법（先端再生バイオ法、先端再生医療・先端バイオ医薬品に関する法律）の改正が2025年2月21日に施行され、再生医療の「治療」は重篤・希少・難治性疾患に限り、指定された医療機関で、審議委員会が治療計画を承認した場合にのみ提供できる枠組みになりました[1]。この出典は、美容目的のSVF添加脂肪注入がこの枠組みのどこに位置づけられるかまでは述べていません。渡航前に、その施設がどの法的枠組みで当該施術を提供しているのかを直接確認してください。","url":"https://worldwiki.io/ja/q/2025年2月施行の韓国の再生医療の法律で-外国人でもsvf豊胸を受けられるのですか"},{"slug":"svf豊胸のあと-しこりや石灰化はできますか-帰国後の乳がん検診に影響しますか","question":"SVF豊胸のあと、しこりや石灰化はできますか？帰国後の乳がん検診に影響しますか？","intent":"informational","language":"ja","short_answer":"報告はあります。40例のシリーズではMRIで12 mm未満の嚢胞が2例、術後24か月のマンモグラフィで微小石灰化が2例ありました。総説では嚢胞形成の頻度として自動分離6.9%、用手分離1.6%が引用されています。日本の学会の治療手順では、こうした所見が乳房画像で乳がんと紛らわしくなる場合があるとされ、長期の経過観察が勧められています。帰国後の検診では施術内容と時期を必ず伝えてください。","url":"https://worldwiki.io/ja/q/svf豊胸のあと-しこりや石灰化はできますか-帰国後の乳がん検診に影響しますか"},{"slug":"アメリカではsvfが規制されていると聞きましたが-どういう経緯ですか","question":"アメリカではSVFが規制されていると聞きましたが、どういう経緯ですか？","intent":"informational","language":"ja","short_answer":"米国FDAは2017年8月24日の警告書で、脂肪由来SVFは21 CFR 1271.10(a)(1)の「最小限の操作」基準を満たさず、医薬品・生物学的製剤としてINDまたは承認済みBLAが必要との立場を示しました[1]。その後2024年9月、第9巡回区控訴裁判所は同日施術の例外（same-surgical-procedure exemption）はSVF施術に適用されないと判断し、2025年10月15日に連邦最高裁が上告審理を受理しませんでした[2]。","url":"https://worldwiki.io/ja/q/アメリカではsvfが規制されていると聞きましたが-どういう経緯ですか"},{"slug":"渡韓前のカウンセリングで-svf豊胸について何を質問しておくべきですか","question":"渡韓前のカウンセリングで、SVF豊胸について何を質問しておくべきですか？","intent":"transactional","language":"ja","short_answer":"確認すべきは主に4点です。(1)使用するSVF分離システムの名称（Celution、Medikhan、Fatstem、Mystemなど複数が存在し、標準化されたプロトコルはありません[5]）、(2)提示された定着率がどの論文のどの集団の数値か、そして施術提供側が執筆した対照群のない研究であることの説明[1][2]、(3)韓国の法的枠組み上どの区分で提供しているか[4]、(4)日本語対応と帰国後のフォロー体制です。","url":"https://worldwiki.io/ja/q/渡韓前のカウンセリングで-svf豊胸について何を質問しておくべきですか"},{"slug":"svf-가슴성형은-한국에서-합법인가요-첨단재생의료-규제를-받나요","question":"SVF 가슴성형은 한국에서 합법인가요? 첨단재생의료 규제를 받나요?","intent":"local","language":"ko","short_answer":"2025년 2월 21일 시행된 첨단재생바이오법 개정에 따라 첨단재생의료 치료는 중대·희귀·난치질환을 대상으로, 지정된 실시기관에서 심의위원회의 치료계획 승인을 받아야 시행할 수 있습니다 [1]. 미용 목적 가슴성형이 이 체계 안에서 어떻게 분류되는지는 제공된 자료가 직접 명시하지 않으므로, 병원에 해당 시술의 규제상 지위를 직접 확인해야 합니다. 참고로 미국 FDA는 지방유래 SVF가 최소조작 기준을 충족하지 못한다고 보아 IND 또는 허가된 BLA를 요구하고 있으며 [2], 당일 시술형 SVF에 대한 예외도 법원에서 부정되었습니다 [3].","url":"https://worldwiki.io/ko/q/svf-가슴성형은-한국에서-합법인가요-첨단재생의료-규제를-받나요"},{"slug":"병원에서-말하는-생착률-77-같은-숫자-어디까지-믿어야-하나요","question":"병원에서 말하는 생착률 77% 같은 숫자, 어디까지 믿어야 하나요?","intent":"commercial","language":"ko","short_answer":"이 수치는 시술을 한 기관의 의료진이 직접 쓴 단일기관 논문에서 나온 값입니다. 2023년 Annals of Plastic Surgery 논문은 왼쪽 가슴 기준 3개월 78.65%, 6개월 77.17%, 18개월 77.48%(n=102)를 보고했고 [1], 2020년 논문은 105명에서 1개월 85.1%, 3개월 75.1%, 6개월 73.7%를 보고했습니다 [2]. 두 연구 모두 대조군이 없고 이해관계가 완전히 독립적이지 않으므로, 여러 병원이 각자 다른 방식으로 측정한 숫자를 그대로 비교하기는 어렵습니다.","url":"https://worldwiki.io/ko/q/병원에서-말하는-생착률-77-같은-숫자-어디까지-믿어야-하나요"},{"slug":"svf를-섞으면-일반-자가지방이식보다-확실히-더-잘-생착된다는-독립적인-근거가-있나요","question":"SVF를 섞으면 일반 자가지방이식보다 확실히 더 잘 생착된다는 독립적인 근거가 있나요?","intent":"research","language":"ko","short_answer":"독립 메타분석 결과는 일관되지 않습니다. 가슴확대만 분석한 메타분석(6편, 353명)에서 CAL은 일반 지방이식보다 생착이 높았지만(SMD 1.79, 95% CI 0.28–3.31) 합병증 차이는 유의하지 않았고(OR 1.34), SVF로 보강한 하위군에서는 생착률 차이가 나타나지 않았습니다 [3]. 여러 부위를 함께 본 메타분석(15편)은 보강군에 유리했으나 이질성이 I² = 97.19%로 매우 높아 효과가 상황에 좌우된다고 보았습니다 [4]. 2026년 9월 기준 독립적인 무작위배정 대조연구는 확인되지 않았습니다.","url":"https://worldwiki.io/ko/q/svf를-섞으면-일반-자가지방이식보다-확실히-더-잘-생착된다는-독립적인-근거가-있나요"},{"slug":"수술-후-석회화나-낭종이-생기면-나중에-유방암-검진에-지장이-있나요","question":"수술 후 석회화나 낭종이 생기면 나중에 유방암 검진에 지장이 있나요?","intent":"informational","language":"ko","short_answer":"2008년 원 보고에서는 40명 중 MRI상 12 mm 미만 낭종 2명, 24개월 시점 유방촬영상 미세석회화 2명, 흉골 섬유화 1명이 관찰되었습니다 [1]. 문헌 고찰에서는 세포 분리 방식에 따라 낭종 형성률이 자동화 6.9%, 수기 1.6%로 인용되었습니다 [3]. 제공된 자료에는 이런 소견이 향후 유방암 검진 판독에 미치는 영향을 정량적으로 다룬 데이터가 없으므로, 검진 시 지방이식 이력을 반드시 알리고 판독의와 상의하는 것이 필요합니다.","url":"https://worldwiki.io/ko/q/수술-후-석회화나-낭종이-생기면-나중에-유방암-검진에-지장이-있나요"},{"slug":"수술하고-몇-개월이-지나야-최종-결과로-볼-수-있나요-초반에-작아지는-건-정상인가요","question":"수술하고 몇 개월이 지나야 최종 결과로 볼 수 있나요? 초반에 작아지는 건 정상인가요?","intent":"informational","language":"ko","short_answer":"보고된 경과를 보면 초기 감소 후 비교적 안정되는 양상입니다. 105명 대상 연구에서 생착률은 1개월 85.1%, 3개월 75.1%, 6개월 73.7%였고 [2], 다른 연구에서는 3개월 78.65%, 6개월 77.17%, 18개월 77.48%로 보고되었습니다 [1]. 다만 이는 단일기관 평균값이며 개인별 변동 범위나 재수술 시점 기준은 제공된 자료에 명시되어 있지 않습니다.","url":"https://worldwiki.io/ko/q/수술하고-몇-개월이-지나야-최종-결과로-볼-수-있나요-초반에-작아지는-건-정상인가요"},{"slug":"마른-체형이라-뺄-지방이-별로-없는데-svf-가슴성형이-가능한가요","question":"마른 체형이라 뺄 지방이 별로 없는데 SVF 가슴성형이 가능한가요?","intent":"commercial","language":"ko","short_answer":"공개된 연구에서 주입량은 상당히 큽니다. 2008년 원 보고는 한쪽 가슴당 평균 약 270 mL를 주입해 최종 100–200 mL 증가를 얻었고 [3], 2023년 단일기관 연구의 평균 주입량은 왼쪽 가슴 기준 162.35 mL였습니다 [1]. 제공된 자료에는 시술이 가능한 최소 체지방량이나 BMI 기준이 없으므로, 본인 지방량으로 어느 정도 주입이 가능한지와 목표 볼륨이 현실적인지를 상담에서 구체적인 mL 단위로 확인해야 합니다.","url":"https://worldwiki.io/ko/q/마른-체형이라-뺄-지방이-별로-없는데-svf-가슴성형이-가능한가요"},{"slug":"유방암-가족력이-있는데-줄기세포-svf-가슴성형을-받아도-되나요","question":"유방암 가족력이 있는데 줄기세포(SVF) 가슴성형을 받아도 되나요?","intent":"informational","language":"ko","short_answer":"제공된 근거로는 답할 수 없는 질문입니다. 문헌 고찰은 VEGF·FGF 신호와 관련한 이론적 종양 발생 우려를 언급하면서 장기 종양학적 데이터가 불충분하다고 정리하고 있습니다 [1]. 유방암 가족력이나 과거력이 있는 환자를 따로 분석한 데이터는 제공된 자료에 없으므로, 성형외과 상담과 별개로 유방외과 전문의에게 본인의 위험도를 평가받고 판단하시는 것이 안전합니다.","url":"https://worldwiki.io/ko/q/유방암-가족력이-있는데-줄기세포-svf-가슴성형을-받아도-되나요"},{"slug":"세포-분리-장비나-방식-자동-vs-수기-에-따라-결과가-달라지나요","question":"세포 분리 장비나 방식(자동 vs 수기)에 따라 결과가 달라지나요?","intent":"comparison","language":"ko","short_answer":"표준화된 CAL 프로토콜은 없고 Celution, Medikhan, Fatstem, Mystem 등 여러 분리 시스템이 사용되고 있습니다 [1]. 인용된 데이터에서는 낭종 형성이 자동화 분리 6.9%, 수기 분리 1.6%로 보고되었습니다 [1]. 다만 이는 서로 다른 연구들을 모은 수치이고 장비별 직접 비교 시험은 제공된 자료에 없으므로, 어떤 장비가 더 낫다고 결론 내릴 근거는 아직 없습니다.","url":"https://worldwiki.io/ko/q/세포-분리-장비나-방식-자동-vs-수기-에-따라-결과가-달라지나요"},{"slug":"网上到处说的-存活率77-是哪来的数据-可信度怎么样","question":"网上到处说的「存活率77%」是哪来的数据？可信度怎么样？","intent":"informational","language":"zh","short_answer":"该数字出自韩国SC301机构自己发表在《Annals of Plastic Surgery》（2023）的384例单中心研究：左乳平均注入162.35 mL，保有率3个月78.65%、6个月77.17%、18个月77.48%（18个月随访n=102）。同一机构2020年的105例报告为1个月85.1%、3个月75.1%、6个月73.7%。这两篇都是经同行评审但由实施机构自身作者撰写、没有对照组的研究，因此只能视为该机构的自报结果，不等于行业平均水平。","url":"https://worldwiki.io/zh-CN/q/网上到处说的-存活率77-是哪来的数据-可信度怎么样"}],"sources":[{"id":27,"title":"A Study on Breast Augmentation Using Fat Grafting With Stromal Vascular Fraction (Shin DJ, Ann Plast Surg 2023;90(4):380-384)","url":"https://pubmed.ncbi.nlm.nih.gov/36881737/","publisher":"Annals of Plastic Surgery","type":"academic","publication_date":"2023-04-01","accessed_at":"2026-11-11 18:00:13"},{"id":28,"title":"Breast Augmentation by Fat Transplantation With Adipose-Derived Stem/Stromal Cells (Shin DJ, Aesthet Surg J Open Forum 2020)","url":"https://pubmed.ncbi.nlm.nih.gov/33791627/","publisher":"Aesthetic Surgery Journal Open Forum","type":"academic","publication_date":"2020-02-07","accessed_at":"2026-11-11 18:00:13"},{"id":152,"title":"Cell-Assisted Lipotransfer for Cosmetic Breast Augmentation: Supportive Use of Adipose-Derived Stem/Stromal Cells, Yoshimura K et al.","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2175019/","publisher":"Aesthetic Plastic Surgery","type":"journal","publication_date":null,"accessed_at":"2026-11-09 18:01:20"},{"id":280,"title":"The Efficacy of Cell-Assisted Lipotransfer Versus Conventional Lipotransfer in Breast Augmentation: A Systematic Review and Meta-Analysis (Europe PMC record, PMID 33452543)","url":"https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1007/s00266-020-02123-0&format=json&resultType=core","publisher":"Aesthetic Plastic Surgery (via Europe PMC)","type":"journal","publication_date":"2021-01-01","accessed_at":"2026-10-28 18:02:02"},{"id":281,"title":"Clinical Efficacy of Adipose-Derived Stem Cell-Enriched Lipotransfer Versus Conventional Fat Grafting: A Systematic Review and Meta-Analysis (Europe PMC record, PMID 42005195)","url":"https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=cell-assisted%20lipotransfer%20breast%20augmentation%20meta-analysis&format=json&resultType=core&pageSize=6","publisher":"Cureus (via Europe PMC)","type":"journal","publication_date":"2026-01-01","accessed_at":"2026-10-28 18:02:04"},{"id":282,"title":"Warning Letter: US Stem Cell Clinic, LLC (524470)","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-stem-cell-clinic-llc-524470-08242017","publisher":"U.S. Food and Drug Administration","type":"government","publication_date":"2017-08-24","accessed_at":"2026-11-09 18:00:37"},{"id":283,"title":"SCOTUS Declines Stem Cell Case, Upholding FDA Oversight of Cell Therapies","url":"https://www.aabb.org/news-resources/news/article/2025/10/15/scotus-declines-stem-cell-case--upholding-fda-oversight-of-cell-therapies","publisher":"AABB (Association for the Advancement of Blood & Biotherapies)","type":"organization","publication_date":"2025-10-15","accessed_at":"2026-11-11 18:00:06"},{"id":93,"title":"첨단재생의료에 대한 환자 접근성은 향상되고, 안전관리는 강화됩니다","url":"https://mohw.go.kr/board.es?mid=a10503000000&bid=0027&list_no=1483481&act=view","publisher":"보건복지부","type":"government","publication_date":null,"accessed_at":"2026-11-09 18:00:30"},{"id":284,"title":"Cell-Assisted Lipotransfer in Breast Augmentation Surgery: Clinical Outcomes and Considerations for Future Research","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8971120/","publisher":"Cureus (via PubMed Central)","type":"journal","publication_date":"2022-03-02","accessed_at":"2026-11-11 18:00:04"}],"providers":[{"slug":"sc301","name":"SC301의원","verified_level":"verified","sponsored":false,"featured":false,"country":"KR","city":"Seoul","url":"https://worldwiki.io/provider/sc301"}],"published_at":"2026-09-14 13:42:07","updated_at":"2026-11-12 05:20:00","verified_at":null}